Indivior (NASDAQ:INDV) Announces Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Indivior (NASDAQ:INDV) issued its quarterly earnings results on Thursday. The company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.17, Zacks reports. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The firm had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million.

Here are the key takeaways from Indivior’s conference call:

• Indivior reported strong 2025 results with SUBLOCADE net revenue of $856M (up 13%), total net revenue of $1.24B (up 4%), and record adjusted EBITDA of $428M (up 20%) with notable margin improvement.
• Management gave 2026 guidance calling for accelerated momentum — mid-teens U.S. SUBLOCADE dispense growth, SUBLOCADE net revenue of $905M–$945M (~8% at midpoint), adjusted EBITDA of $535M–$575M (≈30% growth) and ~ $300M operating cash flow.
• The company completed organizational simplification and set a 2026 non-GAAP operating expense target of ≤$450M after taking $120M of restructuring charges in 2025 (≈$28M cash cost), which should improve leverage but involved upfront costs.
• Indivior strengthened its financial flexibility by paying the $295M DOJ obligation (eliminating a legacy liability), exiting 2025 with net leverage below 1x, and announcing a new $400M opportunistic share repurchase program while prioritizing debt management and commercial-stage M&A.
• Management warned of headwinds in 2026 that pressure total revenue at the midpoint — expected U.S. SUBOXONE Film pricing pressure, lower rest-of-world revenue after optimization, gross-to-net movements, and continued PERSERIS runoff.

Indivior Trading Up 0.2%

INDV stock opened at $33.71 on Friday. The firm has a 50 day moving average of $34.60 and a 200-day moving average of $29.92. The company has a market cap of $4.21 billion, a price-to-earnings ratio of 36.64 and a beta of 0.80. Indivior has a 12-month low of $8.34 and a 12-month high of $38.00.

Analyst Ratings Changes

INDV has been the subject of a number of research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Piper Sandler restated an “overweight” rating and issued a $41.00 price target (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. Northland Securities set a $50.00 price objective on Indivior in a research report on Tuesday, January 20th. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Finally, Morgan Stanley restated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Insider Transactions at Indivior

In other news, Director David E. Wheadon acquired 1,771 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares in the company, valued at $509,439.05. This trade represents a 14.03% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Keith Humphreys bought 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director owned 5,802 shares of the company’s stock, valued at $205,332.78. This represents a 15.42% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 4,871 shares of company stock worth $172,385 over the last ninety days.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP purchased a new position in shares of Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new stake in Indivior during the 2nd quarter valued at $26,000. Financiere des Professionnels Fonds d investissement inc. increased its position in Indivior by 26.6% during the fourth quarter. Financiere des Professionnels Fonds d investissement inc. now owns 11,917 shares of the company’s stock worth $428,000 after buying an additional 2,502 shares in the last quarter. Swiss National Bank raised its holdings in shares of Indivior by 1.5% in the third quarter. Swiss National Bank now owns 193,431 shares of the company’s stock worth $4,664,000 after acquiring an additional 2,900 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Indivior by 1.7% in the fourth quarter. JPMorgan Chase & Co. now owns 211,208 shares of the company’s stock valued at $7,578,000 after acquiring an additional 3,620 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.